Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Oct;37(10):2187–2192. doi: 10.1128/aac.37.10.2187

Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.

D DeMuria 1, A Forrest 1, J Rich 1, J M Scavone 1, L G Cohen 1, P H Kazanjian 1
PMCID: PMC192248  PMID: 8257143

Abstract

Fluconazole pharmacokinetics were evaluated for 10 volunteers with AIDS who had no clinical evidence of gastroenteritis. Single 100-mg intravenous (i.v.) and oral (p.o.) doses were administered in a randomized, crossover design. i.v. doses were delivered by a constant-rate infusion over 30 min. Serum fluconazole concentrations were measured by gas-liquid chromatography. The i.v. and p.o. studies were modelled simultaneously by iterative two-stage analysis, which provided individual parameter estimates and a population pharmacokinetic model. Median areas under the concentration-time curves for i.v. and p.o. studies did not differ (90.6 and 99.3 micrograms/ml.h, respectively). Consistent with this finding, the median fractional bioavailability was 1.1 (range, 0.45 to 1.3), comparable to those in healthy subjects. Serum pharmacokinetics in these AIDS patients were generally similar to published data for healthy volunteers. However, following p.o. dosing, we observed a slightly delayed and highly variable time to maximum concentration in serum (median, 2 h; range, 15 min to 8 h). Data were well described by a linear, two-compartment pharmacokinetic model with first-order absorption and elimination. Repeated-measures analysis of variance found no significant differences among any of the pharmacokinetic parameters between i.v. and p.o. studies. On the basis of our findings, we suggest no change in dosage of p.o. fluconazole in patients with AIDS who show no clinical signs of enteropathy.

Full text

PDF
2192

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berning S. E., Huitt G. A., Iseman M. D., Peloquin C. A. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med. 1992 Dec 17;327(25):1817–1818. doi: 10.1056/NEJM199212173272514. [DOI] [PubMed] [Google Scholar]
  2. Blum R. A., D'Andrea D. T., Florentino B. M., Wilton J. H., Hilligoss D. M., Gardner M. J., Henry E. B., Goldstein H., Schentag J. J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991 May 1;114(9):755–757. doi: 10.7326/0003-4819-114-9-755. [DOI] [PubMed] [Google Scholar]
  3. Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S318–S326. doi: 10.1093/clinids/12.supplement_3.s318. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Debruyne D., Ryckelynck J. P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet. 1993 Jan;24(1):10–27. doi: 10.2165/00003088-199324010-00002. [DOI] [PubMed] [Google Scholar]
  6. Dworkin B., Wormser G. P., Rosenthal W. S., Heier S. K., Braunstein M., Weiss L., Jankowski R., Levy D., Weiselberg S. Gastrointestinal manifestations of the acquired immunodeficiency syndrome: a review of 22 cases. Am J Gastroenterol. 1985 Oct;80(10):774–778. [PubMed] [Google Scholar]
  7. Fletcher C. V., Rhame F. S., Beatty C. C., Simpson M., Balfour H. H., Jr Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy. 1992;12(6):429–434. [PubMed] [Google Scholar]
  8. Forrest A., Ballow C. H., Nix D. E., Birmingham M. C., Schentag J. J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993 May;37(5):1065–1072. doi: 10.1128/aac.37.5.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Foulds G., Wajszczuk C., Weidler D. J., Garg D. J., Gibson P. Steady state parenteral kinetics of fluconazole in man. Ann N Y Acad Sci. 1988;544:427–430. doi: 10.1111/j.1749-6632.1988.tb40440.x. [DOI] [PubMed] [Google Scholar]
  10. Guttman D., Raymond A., Gelb A., Ehya H., Mather U., Mildvan D., Spigland I. Virus-associated colitis in homosexual men: two case reports. Am J Gastroenterol. 1983 Mar;78(3):167–169. [PubMed] [Google Scholar]
  11. Harris S. C., Wallace J. E., Foulds G., Rinaldi M. G. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989 May;33(5):714–716. doi: 10.1128/aac.33.5.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hughes W. T., Kennedy W., Shenep J. L., Flynn P. M., Hetherington S. V., Fullen G., Lancaster D. J., Stein D. S., Palte S., Rosenbaum D. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis. 1991 Apr;163(4):843–848. doi: 10.1093/infdis/163.4.843. [DOI] [PubMed] [Google Scholar]
  13. Hughes W., Leoung G., Kramer F., Bozzette S. A., Safrin S., Frame P., Clumeck N., Masur H., Lancaster D., Chan C. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103. [DOI] [PubMed] [Google Scholar]
  14. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kotler D. P., Gaetz H. P., Lange M., Klein E. B., Holt P. R. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Oct;101(4):421–428. doi: 10.7326/0003-4819-101-4-421. [DOI] [PubMed] [Google Scholar]
  16. Lazar J. D., Wilner K. D. Drug interactions with fluconazole. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S327–S333. doi: 10.1093/clinids/12.supplement_3.s327. [DOI] [PubMed] [Google Scholar]
  17. Levinson W., Bennetts R. W. Cytomegalovirus colitis in acquired immunodeficiency syndrome--a chronic disease with varying manifestations. Am J Gastroenterol. 1985 Jun;80(6):445–447. [PubMed] [Google Scholar]
  18. Niedt G. W., Schinella R. A. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med. 1985 Aug;109(8):727–734. [PubMed] [Google Scholar]
  19. Smith P. D., Quinn T. C., Strober W., Janoff E. N., Masur H. NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med. 1992 Jan 1;116(1):63–77. doi: 10.7326/0003-4819-116-1-63. [DOI] [PubMed] [Google Scholar]
  20. Steimer J. L., Mallet A., Golmard J. L., Boisvieux J. F. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1-2):265–292. doi: 10.3109/03602538409015066. [DOI] [PubMed] [Google Scholar]
  21. Stern J. J., Hartman B. J., Sharkey P., Rowland V., Squires K. E., Murray H. W., Graybill J. R. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med. 1988 Oct;85(4):477–480. doi: 10.1016/s0002-9343(88)80081-0. [DOI] [PubMed] [Google Scholar]
  22. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. doi: 10.1016/s0002-9343(88)80082-2. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES